太景*-KY (4157.TWO)

15.25 +0.20 (+1.33%) 收市：01:30PM CST

太景*-KY

No. 138, Xinming Road
7th Floor Neihu District
Taipei 11470
Taiwan
886 2 8177 7020
https://www.taigenbiotech.com.tw

版塊: Healthcare
行業: Biotechnology
全職員工: 

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. Ming-Chu Hsu Ph.D.	Founder	15k	無	無
Mr. Kuo-Lung Huang	Chairman of the Board, CEO, President & Chief Commercial Officer in Asia	無	無	無
Mr. Richard Lu	Vice President of Finance	無	無	無
Mark Kao	Head of the Accounting Department	無	無	無
Dr. Peter W. Tsao M.B.A., Ph.D.	Vice President Corporate Development	無	無	無

截止 2014年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 TWD。

描述

TaiGen Biopharmaceuticals Holdings Limited, a pharmaceutical company, develops novel therapeutics for transformative diseases worldwide. The company develops Taigexyn (Nemonoxacin), a non-fluorinated quinolone antibiotic for the treatment of bacterial infections. It is also developing Taigexyn for treating community-acquired pneumonia and diabetic foot infection, as well as other bacterial infections; Burixafor, a stem cell mobilizer for stem cell transplantation and chemosenzitization; TG-1000, an influenza antiviral drug for treating influenza A, B, and avian influenza H7N9; and Furaprevir, a hepatitis C virus protease inhibitor for the treatment of chronic hepatitis C. The company was founded in 2001 and is based in Taipei City, Taiwan.

公司管治

截至 無 止，太景*-KY 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。